In this episode of CME on the go, recorded live at FMX in Anaheim, our hosts discuss the complexities of ADHD treatment. They cover initial thoughts on stimulant and non-stimulant medications, dosing guidelines, and the importance of addressing comorbid conditions. Listeners' feedback from a previous ADHD episode is highlighted, emphasizing the need for practical prescribing insights. The hosts also discuss the relevance of shared decision-making and strategies for managing ADHD amid potential substance abuse risks.

After listening to the podcast episode, claim 0.5 AAFP credit by following the provided link.

https://www.aafp.org/assessment/take/19540/e

Learning Objectives

1. Design efficient workflows for managing controlled substances in ADHD treatment, balancing regulatory requirements with patient care.
2. Analyze the pharmacology, clinical applications, and abuse potential of stimulant medications, including considerations for off-label use and misuse in non-ADHD populations.
3. Integrate ADHD medications into treatment plans for patients with comorbid psychiatric conditions, such as depression, to enhance overall therapeutic outcomes.

References and Resources

https://chadd.org/for-adults/medication-management/

Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878-885. doi:10.1111/jcpp.12164

https://chadd.org/for-parents/substance-abuse-and-adhd/

Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood?. Am J Psychiatry. 2008;165(5):553-555. doi:10.1176/appi.ajp.2008.08020237

Journal of Child and Adolescent PsychopharmacologyVol. 32, No. 4

Published Online: 17 May 2022

The Impact of Pharmacotherapy of Childhood-Onset Psychiatric Disorders on the Development of Substance Use Disorders

Authors: Timothy E. Wilens https://orcid.org/0000-0002-5749-8503 [email protected], Diana W. Woodward, Je Deuk Ko, Amy F. Berger, Colin Burke, and Amy M. Yule

Molina BSG, Kennedy TM, Howard AL, et al. Association Between Stimulant Treatment and Substance Use Through Adolescence Into Early Adulthood. JAMA Psychiatry. 2023;80(9):933-941. doi:10.1001/jamapsychiatry.2023.2157

Olagunju AE, Ghoddusi F. Attention-Deficit/Hyperactivity Disorder in Adults. Am Fam Physician. 2024;110(2):157-166.

Attention-Deficit/Hyperactivity Disorder Medications for Adults: Drugs [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Nov. Available from: https://www.ncbi.nlm.nih.gov/books/NBK610422/

Disclosure: It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and, if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity. All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.

Disclaimer: Copyright 2025. AAFP. The views presented in this broadcast are the speaker's own and do not represent those of AAFP. The information presented is for general, educational, or entertainment purposes and should not be considered legal, health, financial, or other advice. AAFP makes no representation as to the accuracy or completeness of the information and is not responsible for results that may arise from its use. Consult an appropriate professional concerning your specific situation and respective governing bodies for applicable laws. Reference to any specific product or entity does not constitute an endorsement or recommendation by AAFP unless specifically stated otherwise. AAFP and the AAFP logo are registered trademarks of American Academy of Family Physicians.